Skip to main content
IRLAB Therapeutics logo

IRLAB Therapeutics — Investor Relations & Filings

Ticker · IRLAB ISIN · SE0012675361 LEI · 549300JAT34LHEI0DH60 ST Manufacturing
Open in API
Filings indexed 157 across all filing types
Latest filing 2021-02-24 Interim / Quarterly Rep…
Country SE Sweden
Listing ST IRLAB

About IRLAB Therapeutics

https://irlab.se/

IRLAB Therapeutics is a research and development company that discovers and develops novel treatments for neurodegenerative diseases, with a primary focus on Parkinson's disease and other central nervous system (CNS) disorders. The company's research originates from Nobel Prize-winning science and is driven by its proprietary Integrative Screening Process (ISP) platform. This systems pharmacology-based discovery engine utilizes an extensive database to generate a pipeline of drug candidates. The company's portfolio includes clinical-stage assets such as Mesdopetam (IRL790), in development for treating levodopa-induced dyskinesia (LIDs), and Pirepemat (IRL752), which is being developed to reduce falls and improve balance in patients with Parkinson's disease.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2020
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Year-end Report January 1 – December 31, 2020' for IRLAB Therapeutics AB. It contains comprehensive financial tables (Operating result, Earnings per share, Cash and cash equivalents), management commentary, and operational updates for the full fiscal year. It is a formal financial report covering a period shorter than a full annual report (10-K) but providing substantive financial data, fitting the definition of an Interim/Quarterly Report (IR). FY 2020
2021-02-24 English
IRLAB announces change in share capital and number of shares following registered directed share issue
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document explicitly announces a 'change in share capital and number of shares following registered directed share issue'. It details the increase in the number of shares and the resulting total number of shares and votes. This directly corresponds to the definition of a Share Issue/Capital Change announcement. The filing type code 'SHA' is the most appropriate classification.
2021-01-29 English
IRLAB meddelar förändring av aktiekapital och antal aktier efter registrerad riktad emission
Share Issue/Capital Change Classification · 98% confidence The document is a formal announcement from IRLAB regarding a change in its share capital and the total number of shares following a directed share issue ('riktad emission'). It explicitly states the increase in shares (3,250,000) and the new total count of shares and votes. This directly relates to changes in the company's capital structure. Based on the definitions, 'Capital/Financing Update' (CAP) is the most appropriate category for announcements concerning fundraising, financing activities, or capital structure changes. It is not a general regulatory filing (RNS) because it fits a specific category, nor is it a share repurchase (POS) as it details an issuance/capital increase.
2021-01-29 Swedish
Major Shareholding Notification 2020
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding percentage by a specific holder ('Fjärde AP-fonden') in 'IRLAB Therapeutics AB'. It explicitly shows the 'Before the transaction' and 'After the transaction' share counts and voting rights, culminating in a new percentage (5.88%). This type of filing, reporting changes in significant ownership thresholds (crossing 5% in this case), corresponds directly to the Major Shareholding Notification category. The code for this is MRQ.
2020-12-30 English
IRLAB Therapeutics carries out a directed share issue in the amount of SEK 130,000,000
Share Issue/Capital Change Classification · 99% confidence The document is a press release announcing that IRLAB Therapeutics has resolved on a 'directed issue of 3,250,000 shares of class A' to raise SEK 130,000,000. This action involves changing the capital structure through the issuance of new shares, which directly relates to fundraising and capital structure changes. This aligns perfectly with the definition for Capital/Financing Update (CAP). Although it involves shares, it is an announcement of a capital raising event, not a general share repurchase (POS) or a general share issue announcement (SHA), as the primary focus is the financing aspect. It is not a full 10-K, IR, or ER, but a specific corporate action announcement.
2020-12-18 English
IRLAB Therapeutics genomför riktad emission om 130 miljoner kronor
Share Issue/Capital Change Classification · 99% confidence The document is a press release titled "IRLAB Therapeutics genomför riktad emission om 130 miljoner kronor" (IRLAB Therapeutics conducts a directed issue of SEK 130 million). The content details the decision by the Board to issue new shares, the amount raised (SEK 130 million), the subscription price, the participating institutional investors, the resulting dilution (approx. 6.3%), and the intended use of the capital (accelerating clinical studies). This activity directly relates to fundraising, financing activities, and changes in the capital structure. This aligns perfectly with the definition for Capital/Financing Update (CAP). It is not an earnings release (ER), an annual report (10-K), or a general regulatory filing (RNS), as it describes a specific corporate financing event.
2020-12-18 Swedish

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.